Skip to main content

AGBT 2022

Experience G4

Join us in Presidential Suite 1745 this week as we present the latest G4 sequencing data, conduct live instrument demonstrations, and share more details about the new Max Read Kits.

AGBT in-suite events include:

Morning Espresso Bar and Poster Viewing
Scheduled Personal G4 Demonstrations
Afternoon Snacks, Refreshments, and Giveaways
Evening Cocktails and Entertainment

Introducing Max Read Kits

Delivering up to 4 billion reads per run, the Max Read Kit offers unparalleled cost and throughput for short read sequencing on a benchtop platform. Come speak to us about your application for more details about customization and capabilities.

Posters

Evaluation of the Singular Genomics G4 Sequencing Platform with Resolution ctDx Assays on cell-free DNA

Bacterial Whole Genome Assembly and Microbial Community Analysis with the G4

Singular Genomics' G4 Platform Technology Assessment

Training and Validation of an Accelerated DeepVariant Model for Germline Exome Analysis on the G4

Application Notes

RNA Sequencing

Single Cell RNA Sequencing

Whole Exome Sequencing

Whole Genome Sequencing

Specialty Applications

HD-seq

XR-seq

Larry Fong

Lawrence Fong, M.D. is the Efim Guzik Distinguished Professor in Cancer Biology in the Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco, where he leads the Cancer Immunotherapy Program. He also co-directs the Parker Institute of Cancer Immunotherapy at UCSF and co-leads the Cancer Immunity and Immunotherapy Program in the Cancer Center. He is a physician-scientist in the Department of Medicine, Division of Hematology/Oncology directing both a translational research program and an NIH-funded research lab. He has focused on cancer immunotherapy for over 20 years and has been involved in both pre-clinical and clinical studies of FDA-approved immunotherapies including sipuleucel-T and immune checkpoint inhibitors. He has also been involved in multiple first-in-human clinical trials including trials of dendritic cell vaccines, ipilimumab and an adenosine receptor antagonist. Dr. Fong’s research examines the mechanisms that underlie clinical response and resistance to immunotherapies. This work includes tracking antigen-specific T cell responses in treated cancer patients and developing biomarkers that are associated with clinical outcomes. The Cancer Immunotherapy Program that he directs performs early phase and high risk clinical trials across different disease indications. This program also includes a translational laboratory that performs mechanistic studies on samples derived from patients undergoing treatment. Throughout his career, Dr. Fong has received multiple awards including the NIH Outstanding Investigator Award.

Dr. Fong obtained his BA from Columbia and MD from Stanford. He completed internal medicine training at University of Washington, and oncology fellowship and post-doctoral training at Stanford in 2002. He then moved to UCSF as an assistant professor where he is now a distinguished professor. He is an elected member of Alpha Omega Alpha and the American Society for Clinical Investigation. He has over 100 publications in journals including NEJM, Nature, Nature Medicine, Cell, Immunity, and Cancer Discovery. He has served on multiple NIH study sections, the NCI Steering Committees for Genitourinary Cancer (GUSC), the NCI Investigational Drugs (IDSC)-Immunotherapy Task Force, the Department of Defense Prostate Cancer Research Program (PCRP) Vision Setting Committee, and NCI Immuno-oncology Translation Network (IOTN) Steering Committee. He has also served on multiple journal editorial boards including the Journal of Clinical Oncology, Journal of Immunotherapy of Cancer, and Cancer Immunology Research.

Dr. Fong cofounded several companies including FWB LLC (acquired by Streamlogic), Techbargains.com LLC (acquired by Exponential), and Keyhole Therapeutics. He has ongoing research collaborations with Abbvie, Amgen, Bavarian Nordic, Bristol Myer Squibb, Dendreon, Janssen, Merck, and Roche/Genentech. He sits on the steering committee of the Roche/Genentech imCORE network. He also has served on multiple scientific advisory boards including Alector (ALEC), Atreca (BCEL), Bioatla (BCAB), Bolt (BOLT), Ideaya (IDYA), Innovent (IVBXF) Nutcracker, RAPT (RAPT), Senti, Soteria, TeneoBio (acquired by Amgen), and Xyphos (acquired by Astellas).